690TiP A phase III, randomized, double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer (mCRPC; CheckMate 7DX)
| Autor: | Drake, C.G. 1, Saad, F. 2, Clark, W.R. 3, Ciprotti, M. 4, Sharkey, B. 5, Subudhi, S.K. 6, Fizazi, K. 7 |
|---|---|
| Zdroj: | In Annals of Oncology September 2020 31 Supplement 4:S546-S546 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|